<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922048</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-011-216</org_study_id>
    <nct_id>NCT03922048</nct_id>
  </id_info>
  <brief_title>Pediatric Postoperative Analgesia Herniorrhaphy Study</brief_title>
  <official_title>A Phase 2, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of HTX-011 for Postoperative Analgesia in Adolescents and Children (≥3 to &lt;17 Years of Age) Undergoing Unilateral Open Inguinal Herniorrhaphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, double-blind study in pediatric subjects undergoing inguinal&#xD;
      herniorrhaphy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 360 subjects will be randomized into one of three age cohorts: Cohort 1 (approximately&#xD;
      128 adolescents ≥12 to &lt;17 years), Cohort 2 (approximately 128 children ≥6 to &lt;12 years), and&#xD;
      Cohort 3 (approximately 104 children ≥3 to &lt;6 years). Cohorts 1 and 2 will be conducted in&#xD;
      two parts: Part A will be dose-ranging and Part B will further evaluate the HTX-011 dose&#xD;
      identified in Part A.&#xD;
&#xD;
      All subjects enrolled in the study will be randomized to receive either HTX-011 via&#xD;
      instillation into the surgical site or bupivacaine HCl 0.25% without epinephrine via&#xD;
      injection into the surgical site. The study will enroll subjects in a staggered sequence&#xD;
      (from oldest to youngest) of the 3 age cohorts. An Interim Review Committee will monitor the&#xD;
      safety of each HTX-011 dose group.&#xD;
&#xD;
      All subjects will be screened within 28 days prior to surgery. On the day of surgery,&#xD;
      eligible subjects will undergo open unilateral herniorrhaphy under general anesthesia and&#xD;
      will receive assigned study drug near the completion of the surgery. Subjects will remain in&#xD;
      the hospital/research facility for 72 hours after the start of study drug administration to&#xD;
      undergo postoperative assessments. After 72 hours, subjects can be discharged and will&#xD;
      undergo follow-up assessments on Days 5, 7 and 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from Time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adolescents ≥12 to &lt;17 years of age (Cohort 1): area under the curve (AUC) of the Numeric Rating Scale of pain intensity scores with activity (NRS-A)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children ≥6 to &lt;12 years of age (Cohort 2): AUC of the Faces-Pain-Scale (FPS)-Revised pain intensity scores</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children ≥3 to &lt;6 years of age (Cohort 3): AUC of the Faces, Legs, Activity, Cry, Consolability (FLACC) scale pain intensity scores</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total postoperative opioid consumption (in IV morphine milligram equivalents)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are opioid-free</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of the Numeric Rating Scale pain intensity scores at rest (NRS-R)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Part A: HTX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescents ≥12 to &lt;17 years of age. A single dose of HTX-011 via instillation into the surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Part A: bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adolescents ≥12 to &lt;17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Part B: HTX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescents ≥12 to &lt;17 years of age. Dose to be determined from Cohort 1 Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Part B: bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adolescents ≥12 to &lt;17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Part A: HTX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children ≥6 to &lt;12 years of age. Dose to be determined from Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Part A: bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children ≥6 to &lt;12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Part B: HTX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children ≥6 to &lt;12 years of age. Dose to be determined from Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Part B: bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children ≥6 to &lt;12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: HTX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children ≥3 to &lt;6 years of age. Dose to be determined from Cohorts 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children ≥3 to &lt;6 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.</description>
    <arm_group_label>Cohort 1 Part A: HTX-011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Luer lock applicator</intervention_name>
    <description>Applicator for instillation.</description>
    <arm_group_label>Cohort 1 Part A: HTX-011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Bupivacaine HCl 0.25% (without epinephrine) 0.5 to 1.0 mL/kg (total dose not to exceed 75 mg).</description>
    <arm_group_label>Cohort 1 Part A: bupivacaine HCl</arm_group_label>
    <arm_group_label>Cohort 1 Part B: bupivacaine HCl</arm_group_label>
    <arm_group_label>Cohort 2 Part A: bupivacaine HCl</arm_group_label>
    <arm_group_label>Cohort 2 Part B: bupivacaine HCl</arm_group_label>
    <arm_group_label>Cohort 3: bupivacaine HCl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>Dose to be determined from Cohort 1.</description>
    <arm_group_label>Cohort 2 Part A: HTX-011</arm_group_label>
    <arm_group_label>Cohort 2 Part B: HTX-011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>Dose to be determined from Cohorts 1 and 2.</description>
    <arm_group_label>Cohort 3: HTX-011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <description>Dose to be determined from Cohort 1 Part A.</description>
    <arm_group_label>Cohort 1 Part B: HTX-011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under&#xD;
             general anesthesia.&#xD;
&#xD;
          -  Has an American Society of Anesthesiologists Physical Status of I, II, or III.&#xD;
&#xD;
          -  Female subjects are eligible only if not pregnant, not lactating, not planning to&#xD;
             become pregnant during the study, sterile; or using acceptable contraceptives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a medical condition such that, in the opinion of the Investigator, participating&#xD;
             in the study would pose a health risk to the subject or confound the postoperative&#xD;
             assessments.&#xD;
&#xD;
          -  Has had a prior ipsilateral inguinal herniorrhaphy.&#xD;
&#xD;
          -  Has a planned concurrent surgical procedure (eg, bilateral herniorrhaphy).&#xD;
&#xD;
          -  Has a pre-existing concurrent acute or chronic painful physical/restrictive condition&#xD;
             expected to require analgesic treatment in the postoperative period for pain.&#xD;
&#xD;
          -  Has underlying history of chronic opioid use or opioid abuse.&#xD;
&#xD;
          -  Has a contraindication or a known or suspected history of hypersensitivity or&#xD;
             clinically significant idiosyncratic reaction to required study medications.&#xD;
&#xD;
          -  Has known or suspected daily use of opioids for 7 or more consecutive days within the&#xD;
             previous 6 months..&#xD;
&#xD;
          -  Has taken any NSAIDs within least 10 days prior to the scheduled surgery.&#xD;
&#xD;
          -  Has taken long-acting opioids within 3 days prior to the scheduled surgery.&#xD;
&#xD;
          -  Has taken any opioids within 24 hours prior to the scheduled surgery.&#xD;
&#xD;
          -  Has been administered bupivacaine within 5 days prior to the scheduled surgery.&#xD;
&#xD;
          -  Has been administered any local anesthetic within 72 hours prior to the scheduled&#xD;
             surgery.&#xD;
&#xD;
          -  Has initiated treatment with study medications within 1 month prior to study drug&#xD;
             administration that can impact pain control.&#xD;
&#xD;
          -  Has been administered systemic steroids within 5 half-lives or 10 days prior to&#xD;
             administration of study drug.&#xD;
&#xD;
          -  Has a medical condition such that, in the opinion of the Investigator, participating&#xD;
             in the study would pose a health risk to the subject or confound the postoperative&#xD;
             assessments.&#xD;
&#xD;
          -  As per subject history and/or medical records, has active infection or is currently&#xD;
             undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
          -  Has uncontrolled anxiety, psychiatric, or neurological disorder.&#xD;
&#xD;
          -  Had a malignancy in the last year, with the exception of nonmetastatic basal cell or&#xD;
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Has a known or suspected history of drug abuse, a positive drug screen on the day of&#xD;
             surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug&#xD;
             screen who are taking an allowed, prescribed medication that is known to result in a&#xD;
             positive drug test (eg, amphetamine and dextroamphetamine for&#xD;
             attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be&#xD;
             eligible for participation in the study at the discretion of the Sponsor. Subjects&#xD;
             taking any marijuana (medical or recreational) are not allowed to participate in the&#xD;
             study.&#xD;
&#xD;
          -  Previously participated in an HTX-011 study.&#xD;
&#xD;
          -  Received an investigational product or device in a clinical trial within 30 days or&#xD;
             within 5 elimination half-lives.&#xD;
&#xD;
          -  Has undergone 3 or more surgeries within 12 months.&#xD;
&#xD;
          -  Has a body mass index (BMI) &gt;35 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erol Onel</last_name>
    <phone>(858) 251-4420</phone>
    <email>HTX011-ct@herontx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Plano Surgical Hospital</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inguinal hernia</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>herniorrhaphy</keyword>
  <keyword>pediatric</keyword>
  <keyword>local anesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

